Professor Rhinology University of Queensland Centre for Clinical Research, Australia
Background: LYR-210 is an implantable matrix intended to release mometasone furoate for 24 weeks to inflamed sinonasal mucosa in chronic rhinosinusitis (CRS) patients. LYR-210 (7500µg) demonstrated clinically relevant symptom improvement and decreased both ethmoid opacification and need for rescue medication at week 24. The quality of life of the LANTERN study patients was evaluated using the 36-item short form health survey, version 2 (SF-36v2).
Methods: Surgically naïve adults with moderate-to-severe CRS who failed previous medical management enrolled in a multicenter, randomized (1:1:1), controlled LANTERN study. Patients received either bilateral administration of LYR-210 (2500µg) (n=23) or LYR-210 (7500µg) (n=21), or sham-procedure control (n=23). The SF-36v2 was completed at baseline and week 24. The mental health component summary (MCS) and its subdomains (vitality, social functioning, role-emotional, mental health), and physical health component summary (PCS) and its subdomains (physical functioning, role-physical, bodily pain, general health) were analyzed as change from baseline. LYR-210 groups were compared to control at a 1-sided significance level of 0.05 using an ANCOVA model.
Results: Both LYR-210 doses significantly improved the mean MCS score by >8 points over control at week 24. LYR-210 (7500µg) achieved statistical significance in each of the 4 MCS subdomains. LYR-210 (2500µg) and LYR-210 (7500µg) numerically increased the mean PCS score compared to control at week 24, with LYR-210 (7500µg) achieving statistical significance in 3 PCS subdomains (physical functioning, role-physical, and bodily pain).
Conclusions: LYR-210 may significantly improve the mental and physical health and quality of life of CRS patients.